Cox regression analysis of MACCE according to levels of pre-CABG, post-CABG 6 hours and post-CABG 24 hours urinary thromboxane metabolite (TXA-M)
| Tertile | Unadjusted | Adjusted* | |||||
| HR | 95% CI | P values | HR | 95% CI | P values | ||
| Pre-CABG | 1 | – | – | 0.075 | – | – | 0.066 |
| 2 | 0.54 | 0.28~1.01 | 0.055 | 0.52 | 0.27~1.03 | 0.062 | |
| 3 | 0.55 | 0.29~1.03 | 0.062 | 0.48 | 0.25~0.95 | 0.036 | |
| Post-CABG 6 hours | 1 | – | – | 0.755 | – | – | 0.564 |
| 2 | 1.21 | 0.64~2.27 | 0.556 | 1.33 | 0.68~2.22 | 0.404 | |
| 3 | 0.92 | 0.50~1.88 | 0.923 | 0.94 | 0.46~1.93 | 0.862 | |
| Post-CABG 24 hours | 1 | – | – | 0.022 | – | – | 0.018 |
| 2 | 2.22 | 1.04~4.71 | 0.038 | 2.67 | 1.20~5.90 | 0.016 | |
| 3 | 2.81 | 1.35~5.85 | 0.006 | 2.86 | 1.34~6.13 | 0.007 | |
Adjusted by all the variables listed in online supplementary table S1 (age, sex, body mass index, current smoking, hypertension, diabetes mellitus, chronic obstructive pulmonary disease, peripheral vascular disease, prior myocardial infarction, chronic kidney disease, ejection fraction, on-pump procedure, aspirin, β-blocker, statins, ACE inhibitors, calcium channel blocker).
CABG, coronary artery bypass graft; MACCE, major adverse cardiac and cerebrovascular events.